DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "CD33-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells" report to their offering.
This pdf report contains information about TCR & CAR engineered T-cells and NK cells released during the month of September 2016. This issue forms part of the subscription service R&D and Business Tracker for TCR & CAR T-Cells and NK Cells which is listed in the "also available" below.
Featured presentations of September 2016 include the pipeline of CD33-targeted immunotherapeutics, the profile of US biotech Eureka Therapeutics and the profile of anti-glypican 3 CAR-T CSG-GPC3 from CARsGen Therapeutics.
The September 2016 issue of our R&D and Business Tracker service about TCR & CAR engineered T-cells and NK cells contains:
R&D and Technology Tracker
- Pipeline changes
- Regulatory news
- Technology validations
Business Tracker for:
- Company updates
- Collaboration
- Licensing
- Merger & acquisitions
- Financing
Clinical Trial Tracker:
- Scientific Publication Tracker
- Featured Cell Therapy Profile: CSG-GPC3
- Featured Company Profile: Eureka Therapuetics
- Featured Target or Technology Pipeline: CD33-Targeted Immunotherapeutics
CD33-Targeted Immunotherapeutics:
- Antibody-Drug Conjugates
- Radio-Immunotherapeutics
- Fc-Engineered Antibodies
- T-Cell and NK Cell Redirecting Bispecific Antibodies
- CAR T-Cells
For more information about this report visit http://www.researchandmarkets.com/research/cwdn28/cd33targeted